Calcified Tissue International

, Volume 89, Issue 6, pp 434–441

Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis

Original Research


We studied the association between bisphosphonate use and risk of gastrointestinal (GI) cancers in a nationwide retrospective cohort from Denmark. All users of bisphosphonates and other drugs against osteoporosis between 1996 and 2006 (n = 103,562) were used as the exposed group, with three age- and gender-matched controls from the general population (n = 310,683) as the nonexposed group. The main outcome was occurrence of cancer of the esophagus, ventricle, small intestine, colon, pancreas, gallbladder or bile duct, or liver. Except for colon cancer, most of the GI cancers were rare. For clodronate and raloxifene, no excess risk was present for any of the GI cancers. For alendronate, an excess risk of esophageal and liver cancer was observed; however, the excess risk was most pronounced at low doses and short duration of observation. No dose–response relationship was present except for colon cancer with alendronate, where a decrease was seen with increasing dose so that at high doses a seemingly protective effect was present (≥1 defined daily dose, HR = 0.29, 95% CI 0.14–0.62). For etidronate, an excess risk of esophageal, liver, pancreas, and gallbladder and bile duct cancers was seen. Again, no relationship with dose or duration of observation was present. An excess risk of esophageal and liver cancers may be seen with alendronate and etidronate. However, the association may not be causal as no dose–response or time relationship was present. For colon cancer, the decline with increasing alendronate dose may be due to a “healthy user” effect.


Bisphosphonate Alendronate Etidronate Raloxifene Esophagus Liver Pancreas Colon Small intestine Stomach Gallbladder Bile duct Cancer 


  1. 1.
    Wysowski DK (2009) Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:89–90PubMedCrossRefGoogle Scholar
  2. 2.
    Terashima T, Hiramatsu K, Shimatani A, Matsuda M, Ogino H, Satomura Y, Noda Y (2006) An esophageal ulcer mimicking advanced esophageal cancer in a patient on alendronate sodium treatment for osteoporosis. Endoscopy 38(2):E37PubMedCrossRefGoogle Scholar
  3. 3.
    Ribeiro A, DeVault KR, Wolfe JT, Stark ME (1998) Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest Endosc. 47:525–528PubMedCrossRefGoogle Scholar
  4. 4.
    de Groen P, Lubbe D, Hirsch L, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick M, Pinkas H, Wang K (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016–1021PubMedCrossRefGoogle Scholar
  5. 5.
    Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JFJ (1995) The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 274:474–477PubMedCrossRefGoogle Scholar
  6. 6.
    Lagergren J, Bergström R, Lindgren A, Nyrén O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831PubMedCrossRefGoogle Scholar
  7. 7.
    Lassen A, Hallas J, de Muckadell OBS (2006) Esophagitis: incidence and risk of esophageal adenocarcinoma—a population-based cohort study. Am J Gastroenterol 101:1193–1199PubMedCrossRefGoogle Scholar
  8. 8.
    Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663PubMedCrossRefGoogle Scholar
  9. 9.
    Nguyen DM, Schwartz J, Richardson P, El-Serag HB (2010) Oral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. Dig Dis Sci 55:3404–3407PubMedCrossRefGoogle Scholar
  10. 10.
    Solomon DH, Patrick A, Brookhart MA (2009) More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 360:1789–1792PubMedCrossRefGoogle Scholar
  11. 11.
    Abrahamsen B, Eiken P, Eastell R (2009) Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 24:1095–1102PubMedCrossRefGoogle Scholar
  12. 12.
    Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V (2010) Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case–control analysis within a UK primary care cohort. BMJ 341:c4444PubMedCrossRefGoogle Scholar
  13. 13.
    Sewing L, Steinberg F, Schmidt H, Göke R (2008) The bisphosphonate zoledronic acid inhibits the growth of HCT-116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis 13:782–789PubMedCrossRefGoogle Scholar
  14. 14.
    Montella L, Addeo R, Palmieri G, Caraglia M, Cennamo G, Vincenzi B, Guarrasi R, Mamone R, Faiola V, Frega N, Capasso E, Maiorino L, Leopardo D, Pizza C, Montesarchio V, Del Prete S (2010) Zoledronic acid in the treatment of bone metastases by hepatocellular carcinoma: a case series. Cancer Chemother Pharmacol 65:1137–1143PubMedCrossRefGoogle Scholar
  15. 15.
    Penel N, Dewas S, Doutrelant P, Clisant S, Yazdanpanah Y, Adenis A (2008) Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis. Support Care Cancer 16:387–392PubMedCrossRefGoogle Scholar
  16. 16.
    Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268PubMedGoogle Scholar
  17. 17.
    Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Laeger 157:3741–3745PubMedGoogle Scholar
  18. 18.
    Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087PubMedCrossRefGoogle Scholar
  19. 19.
    Bagnardi V, Blangiardo M, La Vecchia C, Corrao G (2001) Alcohol consumption and the risk of cancer: a meta-analysis. Alcohol Res Health 25:263–270PubMedGoogle Scholar
  20. 20.
    Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340–1350PubMedCrossRefGoogle Scholar
  21. 21.
    Carroll C, Cooper K, Papaioannou D, Hind D, Pilgrim H, Tappenden P (2010) Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 32:789–803PubMedCrossRefGoogle Scholar
  22. 22.
    Curtis JR, Larson JC, Delzell E, Brookhart MA, Cadarette SM, Chlebowski R, Judd S, Safford M, Solomon DH, Lacroix AZ (2011) Placebo adherence, clinical outcomes, and mortality in the women’s health initiative randomized hormone therapy trials. Med Care 49:427–435PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.The Osteoporosis Clinic, Department of Endocrinology and Internal Medicine (MEA)Aarhus University Hospital THGAarhus CDenmark

Personalised recommendations